- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.03. | NEPHROS INC - 10-K, Annual Report | 1 | SEC Filings | ||
| 08.03. | Nephros, Inc. (NEPH) Q4 2023 Earnings Call Transcript | 1 | Insider Monkey | ||
| 08.03. | Earnings call: Nephros Inc. reports strong growth in Q4 2023 | 1 | Investing.com | ||
| 08.03. | Nephros Inc reports results for the quarter ended in December - Earnings Summary | 2 | Reuters | ||
| 07.03. | Nephros: Q4 Earnings Insights | 1 | Benzinga.com | ||
| 07.03. | Nephros reports Q4 results | 1 | Seeking Alpha | ||
| 07.03. | Nephros, Inc.: Nephros Announces Fourth Quarter and Fiscal Year 2023 Financial Results | 87 | GlobeNewswire (Europe) | Full-Year Net Revenue of $14.2 Million and Fourth-Quarter Net Revenue of $3.3 Million SOUTH ORANGE, NJ, March 07, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - Nephros, Inc. (Nasdaq: NEPH), a leading... ► Artikel lesen | |
| 07.03. | NEPHROS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 06.03. | Earnings Outlook For Nephros | 2 | Benzinga.com | ||
| 29.02. | Nephros, Inc.: Nephros Schedules Conference Call for Fourth Quarter and Fiscal Year 2023 Financial Results | 1 | GlobeNewswire (USA) | ||
| 12.12.23 | Nephros CEO buys 18k shares of the company - filing | 3 | Seeking Alpha | ||
| 06.12.23 | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 06.12.2023 | 456 | Xetra Newsboard | The following instruments on XETRA do have their first trading 06.12.2023 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 06.12.2023
Aktien
1 US1468756044 Carver Bancorp Inc.
2... ► Artikel lesen | |
| 10.11.23 | Earnings call: Nephros Inc. reports significant growth in Q3 2023, driven by strengthened distribution and inventory resilience | 2 | Investing.com | ||
| 09.11.23 | Nephros Inc reports results for the quarter ended in September - Earnings Summary | 2 | Reuters | ||
| 08.11.23 | Nephros GAAP EPS of -$0.02 beats by $0.05, revenue of $3.74M beats by $0.37M | 2 | Seeking Alpha | ||
| 08.11.23 | Nephros: Q3 Earnings Insights | 1 | Benzinga.com | ||
| 08.11.23 | Nephros, Inc.: Nephros Announces Results for Quarter Ended September 30, 2023 | 139 | GlobeNewswire (Europe) | Third-Quarter Net Revenue of $3.7 Million, a 55% Increase Over 2022; Net Loss from Continuing Operations Narrows 85% to $0.2 Million; $1.1 Million in Positive Year-to-Date Net Cash Flows from Operating... ► Artikel lesen | |
| 08.11.23 | NEPHROS INC - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.11.23 | NEPHROS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 01.11.23 | Nephros hires Judy Krandel as Chief Financial Officer | 1 | Seeking Alpha |
Seite:
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ORPEA | 12,582 | -0,66 % | EMEIS PURSUES ITS REFOUNDATION: 2023 Consolidated Financial Results of ORPEA S.A. | Significant improvement in non-financial indicators, with major advances for employees, residents and patients
Health and safety: decline in the work-related accident frequency rate, at 24.8... ► Artikel lesen | |
| NANO-X IMAGING | 8,940 | +0,22 % | Nano-X Imaging Ltd. - 6-K, Report of foreign issuer | ||
| BUTTERFLY NETWORK | 0,780 | +10,56 % | ThinkSono Ltd: ThinkSono Releases Real-Time DVT AI Training Solution for Butterfly Network's Handheld Ultrasound Devices | LONDON, ENGLAND / ACCESSWIRE / April 23, 2024 / ThinkSono, a pioneering provider of AI-driven medical imaging solutions, is proud to announce the release of ThinkSono AI Training, a deep vein thrombosis... ► Artikel lesen | |
| GOODRX | 7,190 | +1,55 % | GoodRx Reports Fourth Quarter and Full Year 2023 Results | SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("GoodRx" or the "Company"), the leading destination for prescription savings in the U.S., has released its financial... ► Artikel lesen | |
| JOINT CORP | 12,230 | +1,24 % | The Joint Corp. Reports Fourth Quarter and Year-end 2023 Financial Results | - Grew 2023 Revenue 16%, System-wide Sales 12%, and System-wide Comp Sales 4% vs. 2022 - - Increased Clinic Count to 935 at Year-end 2023, Initiating Refranchising Program - SCOTTSDALE, Ariz., March... ► Artikel lesen | |
| CARMAT | 3,145 | -0,47 % | CARMAT Announces Its 2023 Annual Results and Provides an Update on Its Progress and Prospects for 2024 | 2023 sales of €2.8 million, i.e. 17 Aeson® implants, including 11 in the last quarter
2024 sales forecast of around €14 million
Active exploration of financing options to extend... ► Artikel lesen | |
| HYPERFINE | 0,845 | +1,68 % | Hyperfine, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results | GUILFORD, Conn., March 21, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable... ► Artikel lesen | |
| PROGYNY | 32,040 | -1,42 % | Progyny, Inc. Announces Details for Its First Quarter 2024 Results Report | ||
| MIMEDX | 6,265 | +0,32 % | Mimedx Group, Cyclacel Pharmaceuticals, Predictive Oncology among healthcare movers | ||
| BIOMERICA | 0,665 | -2,21 % | Biomerica, Inc.: Biomerica Reports Third Quarter 2024 Financial Results | Fiscal Discipline Leads to Improvement as Loss per Share Narrows to $0.27 from $0.40 Amidst Sales Force Expansion for the Nine Months in Fiscal 2024 InFoods IBS Positive Clinical Data to be Presented... ► Artikel lesen | |
| ATRION | 370,00 | -6,09 % | Dividendenbekanntmachungen (14.03.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABRDN PLC GB00BF8Q6K64 0,073 GBP 0,0853 EUR ABRDN PLC ADR US00108N1000 0,3203 USD 0,2925 EUR ACCO BRANDS CORPORATION US00081T1088 0... ► Artikel lesen | |
| ATRICURE | 23,170 | +2,48 % | AtriCure upgraded at Oppenheimer on valuation | ||
| TALKSPACE | 3,120 | +1,30 % | Talkspace Announces Third Quarter 2023 Results | B2B payor revenue grew 132% year-over-year 3Q 2023 Operating expenses of $24.0 million, down 30% year-over-year Reduced Net Loss to $4.4 million and Adjusted EBITDA1 loss to $2.8 million, an improvement... ► Artikel lesen | |
| CASTLE BIOSCIENCES | 20,340 | +4,25 % | Castle Biosciences Inc.: Presentations at EADO Highlight Potential Impact of Castle Biosciences' DecisionDx-Melanoma and DecisionDx-SCC Tests on the Management of Patients with Skin Cancer | If choosing to use a molecular test to rule-out a sentinel lymph node biopsy (SLNB) in patients diagnosed with melanoma, it is important to show that patients foregoing an SLNB have low risk outcomes... ► Artikel lesen | |
| AMWELL | 0,529 | -2,29 % | Amwell Receives Continued Listing Standard Notice From NYSE | Boston, April 04, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leading provider of healthcare software as a service, today announced that it received a notice on April 2, 2024 from the New York... ► Artikel lesen |
NEPHROS INC gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 2,020 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
